Diversifying ADC Payloads as Warheads for Overcoming Tumor Resistance, with Optimized Efficacy, Potency, & Differentiated Mechanisms of Action
As the ADC field becomes increasingly crowded with TOPO-1 and tubulin-based payloads, the pressure is on to identify differentiated mechanisms that can overcome resistance, improve therapeutic index, and deliver meaningful clinical advantage.
Recent billion-dollar transactions, including Novartis’ acquisition of Myricx Bio and its N-myristoyltransferase inhibitor payload platform, Gilead’s $5 billion acquisition of Tubulis to strengthen next-generation ADC technologies, and Johnson & Johnson’s acquisition of Firefly Bio’s degrader antibody conjugate platform, highlight the industry’s confidence in new approaches capable of expanding the therapeutic potential of ADCs.
The 3rd ADC Payload Summit is the only dedicated forum focused exclusively on payload innovation, bringing together 70+ leaders across payload chemistry, discovery biology, translational science, and R&D to tackle these challenges head-on.
Through deep-dive workshops, case studies, panel discussions, and the Brand-New Curated Matchmaking Roundtables, attendees will explore novel payload classes, dual-payload strategies, resistance mechanisms, translational modelling, and emerging approaches beyond traditional cytotoxicity.
Leave this meeting with the solutions to your key challenges around potency, safety, translation, and clinical success to deliver more effective therapies for patients.
I really enjoyed and appreciated the level of openness of the presentations and commentary - that facilitated critical thought and learning, especially with such a multidisciplinary audience.
Senior Investigator, Research
Knowledgeable presenters and ADC research focused topics about emerging ADC payload development.
Associate Director, Product Quality, Sm & Antibodies
The conference, particularly the workshops, was very interactive. In addition, most speakers are leading experts in the field.
Professor & Faculty Fellow
Explore the Full Event Guide:
- 3 Days of Deep-Dive Content Exploring Novel Payload Mechanisms, Resistance Biology & Next-Generation ADC Design
- 70+ ADC Leaders Across Payload Chemistry, Biology, Discovery & Translational R&D
- 2 Interactive Pre-Conference Workshops on Dual Payload ADCs & Expanding the Therapeutic Window
- Brand-New Curated Matchmaking Roundtables Connecting You with Potential Partners, Collaborators & Solution Providers
- Exclusive Case Studies, Panels & Discussions on Non-Cytotoxic Payloads, Multi-Payload Strategies & Overcoming TOPO-1/Tubulin Resistance
Expert Speaker Faculty
Official Partners:
Attending Companies Include
Explore the Agenda
Discover the complete agenda featuring novel payload mechanisms, dual-payload ADCs, resistance biology, therapeutic index optimisation, and the industry leaders redefining ADC payload innovation.
Partner With the ADC Payload Community
Position your organization alongside 70+ senior payload, chemistry, biology, and translational R&D leaders actively seeking technologies, expertise, and collaborations to accelerate next-generation ADC development.
Join 70+ ADC Payload Leaders
Connect with scientists and decision-makers from biopharma and biotech companies tackling the industry's biggest challenges, from overcoming resistance and diversifying payloads to improving clinical translation.